Silvana Valdebenito1, Daniela D'Amico1,2, Eliseo Eugenin1. 1. Department of Neuroscience, Cell Biology, and Anatomy, University of Texas Medical Branch (UTMB), Galveston, Texas. 2. Department of Biomedicine and Clinic Neuroscience, University of Palermo, Palermo, Italy.
Abstract
BACKGROUND: Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide, a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and, in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterogeneity, mechanisms of therapeutic resistance, and new technological approaches to identify new treatments for GBM. The combination of biology and computer resources allow the use of algorithms to apply artificial intelligence and machine learning approaches to identify potential therapeutic pathways and to identify new drug candidates. CONCLUSION: These new approaches will generate a better understanding of GBM pathogenesis and will result in novel treatments to reduce or block the devastating consequences of brain cancers.
BACKGROUND:Glioblastoma (GBM) is a highly aggressive primary brain tumor. Currently, the suggested line of action is the surgical resection followed by radiotherapy and treatment with the adjuvant temozolomide, a DNA alkylating agent. However, the ability of tumor cells to deeply infiltrate the surrounding tissue makes complete resection quite impossible, and, in consequence, the probability of tumor recurrence is high, and the prognosis is not positive. GBM is highly heterogeneous and adapts to treatment in most individuals. Nevertheless, these mechanisms of adaption are unknown. RECENT FINDINGS: In this review, we will discuss the recent discoveries in molecular and cellular heterogeneity, mechanisms of therapeutic resistance, and new technological approaches to identify new treatments for GBM. The combination of biology and computer resources allow the use of algorithms to apply artificial intelligence and machine learning approaches to identify potential therapeutic pathways and to identify new drug candidates. CONCLUSION: These new approaches will generate a better understanding of GBM pathogenesis and will result in novel treatments to reduce or block the devastating consequences of brain cancers.
Authors: Philipp Kickingereder; David Bonekamp; Martha Nowosielski; Annekathrin Kratz; Martin Sill; Sina Burth; Antje Wick; Oliver Eidel; Heinz-Peter Schlemmer; Alexander Radbruch; Jürgen Debus; Christel Herold-Mende; Andreas Unterberg; David Jones; Stefan Pfister; Wolfgang Wick; Andreas von Deimling; Martin Bendszus; David Capper Journal: Radiology Date: 2016-09-16 Impact factor: 11.105
Authors: Corbin A Rayfield; Fillan Grady; Gustavo De Leon; Russell Rockne; Eduardo Carrasco; Pamela Jackson; Mayur Vora; Sandra K Johnston; Andrea Hawkins-Daarud; Kamala R Clark-Swanson; Scott Whitmire; Mauricio E Gamez; Alyx Porter; Leland Hu; Luis Gonzalez-Cuyar; Bernard Bendok; Sujay Vora; Kristin R Swanson Journal: JCO Clin Cancer Inform Date: 2018-12
Authors: Howard Colman; Li Zhang; Erik P Sulman; J Matthew McDonald; Nasrin Latif Shooshtari; Andreana Rivera; Sonya Popoff; Catherine L Nutt; David N Louis; J Gregory Cairncross; Mark R Gilbert; Heidi S Phillips; Minesh P Mehta; Arnab Chakravarti; Christopher E Pelloski; Krishna Bhat; Burt G Feuerstein; Robert B Jenkins; Ken Aldape Journal: Neuro Oncol Date: 2009-10-20 Impact factor: 12.300
Authors: Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes Journal: Cancer Cell Date: 2010-01-19 Impact factor: 31.743
Authors: Akash Kumar; Evan A Boyle; Mari Tokita; Andrei M Mikheev; Michelle C Sanger; Emily Girard; John R Silber; Luis F Gonzalez-Cuyar; Joseph B Hiatt; Andrew Adey; Choli Lee; Jacob O Kitzman; Donald E Born; Daniel L Silbergeld; James M Olson; Robert C Rostomily; Jay Shendure Journal: Genome Biol Date: 2014-12-03 Impact factor: 13.583
Authors: Nicole R Parker; Amanda L Hudson; Peter Khong; Jonathon F Parkinson; Trisha Dwight; Rowan J Ikin; Ying Zhu; Zhangkai Jason Cheng; Fatemeh Vafaee; Jason Chen; Helen R Wheeler; Viive M Howell Journal: Sci Rep Date: 2016-03-04 Impact factor: 4.379
Authors: Caterina Brighi; Paul J Keall; Lois C Holloway; Amy Walker; Brendan Whelan; Philip C de Witt Hamer; Niels Verburg; Farhannah Aly; Cathy Chen; Eng-Siew Koh; David E J Waddington Journal: Neurooncol Adv Date: 2022-08-19